Loading...

Isodiol International

CNSX:ISOL
Snowflake Description

Imperfect balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
ISOL
CNSX
CA$36M
Market Cap
  1. Home
  2. CA
  3. Pharmaceuticals & Biotech
Company description

Isodiol International Inc. engages in the development, marketing, distribution, and sale of hemp-based consumer products and solutions in Canada, Latin America, Asia, and Europe. The last earnings update was 141 days ago. More info.


Add to Portfolio Compare Print
  • Isodiol International has significant price volatility in the past 3 months.
ISOL Share Price and Events
7 Day Returns
-26.2%
CNSX:ISOL
2.6%
CA Pharmaceuticals
-0.2%
CA Market
1 Year Returns
-83.2%
CNSX:ISOL
0.4%
CA Pharmaceuticals
-2.8%
CA Market
ISOL Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Isodiol International (ISOL) -26.2% -38% -53.4% -83.2% - -
CA Pharmaceuticals 2.6% -11.4% -27.3% 0.4% 502.6% 397.9%
CA Market -0.2% -0.4% -2.3% -2.8% 7.6% 0%
1 Year Return vs Industry and Market
  • ISOL underperformed the Pharmaceuticals industry which returned 0.4% over the past year.
  • ISOL underperformed the Market in Canada which returned -2.8% over the past year.
Price Volatility
ISOL
Industry
5yr Volatility vs Market

Value

 Is Isodiol International undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Isodiol International. This is due to cash flow or dividend data being unavailable. The share price is CA$0.62.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Isodiol International's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Isodiol International's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
CNSX:ISOL PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in CAD CA$-1.57
CNSX:ISOL Share Price ** CNSX (2019-07-19) in CAD CA$0.62
Canada Pharmaceuticals Industry PE Ratio Median Figure of 11 Publicly-Listed Pharmaceuticals Companies 18.29x
Canada Market PE Ratio Median Figure of 538 Publicly-Listed Companies 15.08x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Isodiol International.

CNSX:ISOL PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= CNSX:ISOL Share Price ÷ EPS (both in CAD)

= 0.62 ÷ -1.57

-0.4x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Isodiol International is loss making, we can't compare its value to the CA Pharmaceuticals industry average.
  • Isodiol International is loss making, we can't compare the value of its earnings to the Canada market.
Price based on expected Growth
Does Isodiol International's expected growth come at a high price?
Raw Data
CNSX:ISOL PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.4x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Canada Pharmaceuticals Industry PEG Ratio Median Figure of 7 Publicly-Listed Pharmaceuticals Companies 1.16x
Canada Market PEG Ratio Median Figure of 249 Publicly-Listed Companies 1.16x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Isodiol International, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Isodiol International's assets?
Raw Data
CNSX:ISOL PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in CAD CA$2.25
CNSX:ISOL Share Price * CNSX (2019-07-19) in CAD CA$0.62
Canada Pharmaceuticals Industry PB Ratio Median Figure of 144 Publicly-Listed Pharmaceuticals Companies 2.24x
Canada Market PB Ratio Median Figure of 2,442 Publicly-Listed Companies 1.44x
CNSX:ISOL PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= CNSX:ISOL Share Price ÷ Book Value per Share (both in CAD)

= 0.62 ÷ 2.25

0.28x

* Primary Listing of Isodiol International.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Isodiol International is good value based on assets compared to the CA Pharmaceuticals industry average.
X
Value checks
We assess Isodiol International's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Isodiol International has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Isodiol International expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Isodiol International has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
95.4%
Expected Pharmaceuticals industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Isodiol International expected to grow at an attractive rate?
  • Unable to compare Isodiol International's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Isodiol International's earnings growth to the Canada market average as no estimate data is available.
  • Unable to compare Isodiol International's revenue growth to the Canada market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
CNSX:ISOL Future Growth Rates Data Sources
Data Point Source Value (per year)
Canada Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 95.4%
Canada Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 54.1%
Canada Market Earnings Growth Rate Market Cap Weighted Average 14%
Canada Market Revenue Growth Rate Market Cap Weighted Average 5.7%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
CNSX:ISOL Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (6 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in CAD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
CNSX:ISOL Future Estimates Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
CNSX:ISOL Past Financials Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income *
2018-12-31 30 -46 -56
2018-09-30 29 -40 -37
2018-06-30 26 -34 -36
2018-03-31 19 -23 -36
2017-12-31 14 -8 -13
2017-09-30 8 -6 -14
2017-06-30 3 -5 -8
2017-03-31 0 -3 -4

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Isodiol International is high growth as no earnings estimate data is available.
  • Unable to determine if Isodiol International is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
CNSX:ISOL Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (6 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Isodiol International Company Filings, last reported 6 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:ISOL Future Estimates Data
Date (Data in CAD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
CNSX:ISOL Past Financials Data
Date (Data in CAD Millions) EPS *
2018-12-31 -1.57
2018-09-30 -1.19
2018-06-30 -1.35
2018-03-31 -1.72
2017-12-31 -0.90
2017-09-30 -1.51
2017-06-30 -1.50
2017-03-31 -1.35

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Isodiol International will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Take a look at our analysis of ISOL’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. Isodiol International's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. Isodiol International's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Isodiol International's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Canada market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Canada market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Isodiol International has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Isodiol International performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Isodiol International's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Isodiol International does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Isodiol International's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Isodiol International's 1-year growth to the CA Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Isodiol International's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Isodiol International Company Filings, last reported 6 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:ISOL Past Revenue, Cash Flow and Net Income Data
Date (Data in CAD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 29.83 -55.81 48.01 0.75
2018-09-30 28.58 -37.49 42.90 0.94
2018-06-30 25.61 -36.19 34.50 0.81
2018-03-31 19.14 -36.02 30.26 0.60
2017-12-31 13.80 -13.19 10.20 0.10
2017-09-30 7.96 -14.26 7.90 0.12
2017-06-30 3.05 -7.59 5.41 0.14
2017-03-31 0.36 -4.29 3.05 0.14

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Isodiol International has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Isodiol International has efficiently used its assets last year compared to the CA Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Isodiol International improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Isodiol International's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Isodiol International has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Isodiol International's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Isodiol International's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Isodiol International's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • Isodiol International's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Isodiol International's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 2.7x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Isodiol International Company Filings, last reported 6 months ago.

CNSX:ISOL Past Debt and Equity Data
Date (Data in CAD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 91.24 8.25 2.50
2018-09-30 105.98 2.85 3.27
2018-06-30 113.46 0.45 11.52
2018-03-31 47.77 0.00 15.55
2017-12-31 52.92 0.00 26.48
2017-09-30 14.27 0.25 0.87
2017-06-30 11.48 0.38 1.00
2017-03-31 1.90 0.25 0.72
  • Isodiol International's level of debt (9%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if Isodiol International's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Isodiol International has less than a year of cash runway based on current free cash flow.
  • Isodiol International has less than a year of cash runway if free cash flow continues to grow at historical rates of 135.6% each year.
X
Financial health checks
We assess Isodiol International's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Isodiol International has a total score of 2/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Isodiol International's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Isodiol International dividends.
If you bought CA$2,000 of Isodiol International shares you are expected to receive CA$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Isodiol International's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Isodiol International's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
CNSX:ISOL Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
North America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 2.8%
Canada Market Average Dividend Yield Market Cap Weighted Average of 337 Stocks 3.5%
Canada Minimum Threshold Dividend Yield 10th Percentile 1.1%
Canada Bottom 25% Dividend Yield 25th Percentile 2.1%
Canada Top 25% Dividend Yield 75th Percentile 5.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

CNSX:ISOL Future Dividends Estimate Data
Date (Data in CA$) Dividend per Share (annual) Avg. No. Analysts

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Isodiol International has not reported any payouts.
  • Unable to verify if Isodiol International's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Isodiol International's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Isodiol International has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Isodiol International's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Isodiol International afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Isodiol International has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Isodiol International's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Marcos Agramont
COMPENSATION CA$319,200
TENURE AS CEO 2.2 years
CEO Bio

Mr. Marcos Agramont has been Chief Executive Officer and Director at Isodiol International Inc. since May 10, 2017 and is its President. Mr. Agramont served as Chief Operating Officer of Laguna Blends Inc. since March 28, 2017. He served as Chief Operations Officer EVR Premium Brands/Tree of Kindness Inc. from November 2015 to March 2017. He served as Director of Operations HempMeds/Medical Marijuana Inc. January 2013 to November 2015. He worked in Distribution The Coca-Cola Refreshments January 2011 to December 2012.

CEO Compensation
  • Marcos's compensation has increased whilst company is loss making.
  • Marcos's remuneration is higher than average for companies of similar size in Canada.
Management Team Tenure

Average tenure of the Isodiol International management team in years:

0.8
Average Tenure
  • The average tenure for the Isodiol International management team is less than 2 years, this suggests a new team.
Management Team

Marcos Agramont

TITLE
CEO, President & Director
COMPENSATION
CA$319K
TENURE
2.2 yrs

Eli Dusenbury

TITLE
Chief Financial Officer
COMPENSATION
CA$154K
TENURE
0.9 yrs

Patrick Ogle

TITLE
COO & Director
COMPENSATION
CA$337K
TENURE
0.8 yrs

Marvin Washington

TITLE
VP of Business Development & Director
COMPENSATION
CA$13K

Soheil Samimi

TITLE
COMPENSATION
CA$52K
TENURE
0.8 yrs

Kevin Swadish

TITLE
Chief Revenue Officer
TENURE
0.4 yrs
Board of Directors Tenure

Average tenure of the Isodiol International board of directors in years:

0.9
Average Tenure
  • The average tenure for the Isodiol International board of directors is less than 3 years, this suggests a new board.
Board of Directors

Marcos Agramont

TITLE
CEO, President & Director
COMPENSATION
CA$319K
TENURE
2.2 yrs

Patrick Ogle

TITLE
COO & Director
COMPENSATION
CA$337K
TENURE
0.8 yrs

Marvin Washington

TITLE
VP of Business Development & Director
COMPENSATION
CA$13K
TENURE
0.9 yrs

H. Raza

TITLE
Member of Medical Advisory Board

Amit Mathur

TITLE
Member of Medical Advisory Board
TENURE
1.5 yrs

Barinder Rasode

TITLE
Member of Advisory Board
TENURE
0.9 yrs

David Putrino

TITLE
Member of Medical Advisory Board
TENURE
0.8 yrs

Leonardo Matesanz

TITLE
Director
COMPENSATION
CA$60K
TENURE
0.7 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (CA$) Value (CA$)
12. Apr 19 Buy Marcos Agramont Individual 29. Mar 19 29. Mar 19 250,000 CA$1.35 CA$337,500
03. Apr 19 Buy Leonardo Matesanz Individual 29. Mar 19 29. Mar 19 250,000 CA$1.35 CA$337,500
19. Feb 19 Buy Elvis Monroe Llc Company 14. Feb 19 14. Feb 19 521,260 CA$1.27 CA$662,000
05. Dec 18 Sell Amirghasem Samimi-Ardestani Individual 13. Dec 17 24. Aug 18 -402,000 CA$15.67 CA$-4,164,857
18. Oct 18 Sell 1104255 B.C. Ltd. Company 08. Jan 18 24. Aug 18 -616,350 CA$15.22 CA$-5,478,433
18. Oct 18 Buy 1104255 B.C. Ltd. Company 09. Jan 18 03. Aug 18 306,190 CA$14.18 CA$2,101,717
17. Oct 18 Sell 1104255 B.C. Ltd. Company 04. Dec 17 24. Aug 18 -501,500 CA$19.71 CA$-5,722,399
17. Oct 18 Buy 1104255 B.C. Ltd. Company 12. Dec 17 10. Aug 18 514,900 CA$15.96 CA$5,479,646
X
Management checks
We assess Isodiol International's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Isodiol International has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

The Isodiol International (CNSX:ISOL) Share Price Is Down 71% So Some Shareholders Are Rather Upset

See our latest analysis for Isodiol International Isodiol International isn't a profitable company, so it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). … We'd recommend taking a very close look at the stock (and any available forecasts), before considering a purchase, because the share price is not correlated with the revenue growth, that's for sure. … A Different Perspective While Isodiol International shareholders are down 71% for the year, the market itself is up 0.3%.

Simply Wall St -

How Does Investing In Isodiol International Inc. (CNSX:ISOL) Impact The Volatility Of Your Portfolio?

Check out our latest analysis for Isodiol International What ISOL's beta value tells investors Given that it has a beta of 1.7, we can surmise that the Isodiol International share price has been fairly sensitive to market volatility (over the last 5 years). … Because it takes less capital to move the share price of a small company like this, when a stock this size is actively traded it is quite often more sensitive to market volatility than similar large companies. … What this means for you: Beta only tells us that the Isodiol International share price is sensitive to broader market movements.

Simply Wall St -

Could The Isodiol International Inc. (CNSX:ISOL) Ownership Structure Tell Us Something Useful?

As Nassim Nicholas Taleb said, 'Don’t tell me what you think, tell me what you have in your portfolio.' Isodiol International is a smaller company with a market capitalization of CA$52m, so it may still be flying under the radar of many institutional investors. … View our latest analysis for Isodiol International CNSX:ISOL Ownership Summary, May 17th 2019 What Does The Institutional Ownership Tell Us About Isodiol International? … Private Company Ownership We can see that Private Companies own 24%, of the shares on issue.

Simply Wall St -

Company Info

Description

Isodiol International Inc. engages in the development, marketing, distribution, and sale of hemp-based consumer products and solutions in Canada, Latin America, Asia, and Europe. It develops and manufactures phytoceutical consumer products using pharmaceutical and nutraceutical grade phytochemical compounds. The company offers pharmaceutical grade cannabinoid crystalline isolates derived from exempt parts of the hemp plant, as well as micro-encapsulations and nanotechnology for consumable and topical skin care products. It is also involved in manufacturing and distributing hemp oil and nicotine e-liquids, as well as personal care products; and producing bioactive cannabinoids that are used in pharmaceutical applications, including life-threatening and non-life-threatening illnesses, as well as the provision of apparel and merchandising solutions. The company is headquartered in Vancouver, Canada.

Details
Name: Isodiol International Inc.
ISOL
Exchange: CNSX
Founded:
CA$36,071,933
58,180,538
Website: http://isodiol.com
Address: Isodiol International Inc.
200 Granville Street,
Suite 2710,
Vancouver,
British Columbia, V6C 1S4,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
CNSX ISOL Common Shares Canadian National Stock Exchange CA CAD 19. May 2017
DB LB6B Common Shares Deutsche Boerse AG DE EUR 19. May 2017
Number of employees
Current staff
Staff numbers
57
Isodiol International employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/07/20 00:45
End of day share price update: 2019/07/19 00:00
Last estimates confirmation: 2018/07/30
Last earnings filing: 2019/03/01
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/03/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.